Gene-Edited Lymphocytes and the Path Toward “Off-the-Shelf” Therapy Against Cervical Cancer

Researchers from Japan demonstrate that gene editing can enhance the effectiveness of rejuvenated cytotoxic T lymphocytes for targeted immunotherapy.

Rejuvenated cytotoxic T lymphocytes (rejTs) constitute a promising approach for treating cervical cancer. However, the rejection of rejTs by the host’s immune system is a major hurdle. In a recent study, researchers from Japan demonstrated how gene-edited rejTs can enable them to evade cytotoxic T cells and natural killer cells while also exhibiting enhanced anti-tumor activity. Their efforts could pave the way to true “off-the-shelf” treatment for cervical cancer.

Login Or Register To Read Full Story